Background
Malignant fibrous histiocytoma (MFH) is one of the most common soft tissue sarcomas of adulthood and has been reported in various organs. The site of primary origin tends to be mainly in the extremities followed by the trunk, the head, and the neck [
1]. MFH are rare tumors within the central nervous system. However, they have been reported in the brain, dura mater, cranial bones, spine and peripheral nerves [
2,
3]. Radiotherapy is one of the most important treatments of malignant tumors in the head and neck region, but it is known to induce major side effects such as radionecrosis and oncogenesis. MFH has been reported to occur with increased frequency in patients who have been treated with radiotherapy for malignant disease [
4]. The purpose of this report is to improve the understanding of the clinical behavior, predictors of biological aggressiveness, and histological and immunohistochemical features of MFH after radiotherapy for medulloblastoma of the cerebellar vermis.
Discussion
MFH is one of the potentially devastating sarcomas in middle-aged or elderly adults, frequently arising from the proximal end of the extremities and in the retroperitoneum [
7]. It is uncommon in the head and neck region, its frequency in this region being only 1% to 3% of all MFHs [
8]. Clinical manifestations of intracranial MFH are various and mainly depend on the location of the tumor. Occipital MFH has no distinct clinical feature that could aid in its recognition. The diagnosis of MFH is based primarily upon excellent sampling in conjunction with a targeted panel of immunohistochemistry [
9]. MFH tumor is composed of an admixture of spindle-shaped fibroblastic tumor cells and bizarre mononuclear histiocytic tumor cells arranged in a storiform pattern with some multinucleated giant cells [
7]. Immuno-positivity for vimentin, CD68 and Ki-67 has been demonstrated in MFH and is helpful for diagnosis. The tumor tissue should be immune-negative for S-100 protein and cytokeratins. The differential diagnosis of MFH can be difficult because of its similarity to other sarcomas composed of spindle cells, such as spindle cell carcinoma, carcinosarcoma and fibrosarcoma. Sometimes, microscopy with routine staining does not allow distinction of this sarcoma from others, especially when the cells are pleomorphic. Although the characteristic patterns, such as the storiform and antler-like patterns, are useful, immunohistochemical staining was helpful for the diagnosis in our case.
Brieger
et al. describe two patients with Lynch syndrome-associated MFH. Both patients carried a MSH2 germline mutation and a mutator phenotype with loss of MSH2 expression could be demonstrated in both MFH [
10]. This finding further supports the potential risk of patients with Lynch syndrome to develop a MFH as a consequence of the underlying MMR gene germline mutation [
10,
11]. In our case, the genomic mutations in MLH1 or MSH2 were not detected, and the clinical presentation also did not confirm the diagnosis of Lynch syndrome-associated MFH.
MFH has been reported to be more common among patients who have received radiotherapy [
12]. Ionized radiation is clearly known to trigger sarcoma formation [
13]. The following criteria for defining a radiation induced sarcoma (RIS) have been proposed by Cahan
et al. [
14]: (1) evidence of an initial distinct malignant tumor different from the subsequent sarcoma; (2) development of the second malignant tumor in an irradiated field; (3) long interval between radiation and development of the sarcoma (a latency period of not less than five years); and (4) histological confirmation of sarcoma. The present case fulfilled all these criteria.
It is difficult to analyze the relationship between the total irradiation dose received and the incidence of RIS of the head and neck. Kirova
et al. [
15] showed that most reported cases of RIS after breast irradiation occurred after the administration of 60 to 80 Gy, with a minimal dose of 10 Gy, in standard fractions. Karlsson
et al. [
16] found that the risk of sarcoma other than angiosarcomas increased linearly with a total dose of 150 to 200 J, stabilizing at higher energies. Pitcher
et al. [
5] believe that RIS may appear following radical radiation therapy regardless of the photon energy. However, no available studies provide data on the relationship between the prescribed radiation dose and RIS. RIS typically occurs within or at the edge of the radiation field [
6]. Radiation doses greater than 50 Gy cause complete devitalization and bone death, while lower doses greater than 30 Gy are associated with permanent damage to the reparative mechanisms [
17]. The edge of the radiation field is, therefore, at particular risk for the development of a secondary malignancy. The lack of homogeneity of the dose at the periphery of the radiation field also results in an area that has received less radiation than the putative tumor dose. The radiation dose here may be insufficient to kill all viable cells, but may be sufficient to cause cell damage and genetic mutations. A disorganized reparative proliferation may then act as an initiating factor in tumor development.
The RIS is characterized by an aggressive behavior, with a high incidence of local recurrence and distant metastasis [
18]. In our patient, the recurrent disease and distant metastasis did not occur within a few months postoperatively. The overall five-year survival of RIS ranges between 10% and 30% [
18,
19]. Most papers quote a poor outcome for RIS in the head and neck; for instance, Mark
et al. [
20] reported a year disease-free survival of only 8%. Wang
et al. [
21] reported that the five-year disease-free survival and five-year overall survival rates of radiation-induced MFH of the sinonasal tract were 0 and 5.9%.
The preferred treatment is surgical resection whenever the site and size of tumor allow it. Radical
en bloc resection is required because of the aggressiveness of MFH, both locally and remotely [
22]. Sabesan
et al. [
23] reported that marginal resection of MFH of the head and neck carries a local recurrence rate of up to 85%, whereas radical resection has a local recurrence risk of only 27%. Because of the technical difficulty of determining adequate surgical margins and the poor healing and wound complications associated with radiation changes, surgical management of RIS in the posterior fossa is also challenging. Radiation therapy for radiation-induced MFH is effective in some cases but not in others [
24]. The effectiveness of chemotherapy is also controversial and has yet to demonstrate definitive benefit [
9]. Ettinger
et al. [
25] reported excellent results using postoperative cisplatin and doxorubicin in patients with non-metastatic osteosarcoma. A recent study by Hugate
et al. [
26] reported that neoadjuvant chemotherapy (intraarterial cisplatin and intravenous doxorubicin) improved survival rates of primary high-grade extremity osteosarcoma and MFH of the bone. Kocer
et al. [
27] showed that neoadjuvant chemotherapy was an effective method for radiation-induced sternal MFH. In planning the surgical resection, the size of the tumor before chemotherapy should be considered as the initial size and surgical margins should be determined accordingly. Ko
et al. [
28] reported that exploitation of more effective chemotherapy is necessary to improve the tumor-free survival of patients with radiation-induced MFH in the head and neck region. With so few reported cases of RIS, it is difficult to establish the optimal treatment. Initial radical surgery is usually the effective treatment for achieving long-term survival because adjuvant and palliative treatments are not so effective [
1].
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GBZ, JL and JTZ reviewed the literature and drafted the manuscript. GBZ, PFZ, LJH and JTZ were clinically responsible for the patient’s care and revised the manuscript. JL and LJH were responsible for the pathology and radiological images. All authors read and approved the final manuscript.